# Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

> **NCT01680341** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 272 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/insulin aspart
- **DRUG:** insulin degludec/insulin aspart

## Key facts

- **NCT ID:** NCT01680341
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-31
- **Primary completion:** 2013-08-22
- **Final completion:** 2013-08-22
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2018-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01680341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01680341, "Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01680341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*